Ebere Ikenna

Ikenna Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapies that target key signaling pathways in cancer. The company's primary focus is on the Hippo pathway, specifically targeting TEAD transcription factors to treat cancers such as mesothelioma and other solid tumors. Their lead program, IK-930, is a TEAD inhibitor designed to address tumors with Hippo pathway mutations or those that have developed resistance to other therapies. Additionally, Ikenna is advancing programs targeting the Aryl Hydrocarbon Receptor (AHR) and the RAS/MAPK pathway to overcome immune suppression and treatment resistance in various oncology indications.